Meeting
2019 ASCO Annual Meeting
End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).
Authors
Sandra M. Swain
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, DC
Sandra M. Swain , David Miles , Sung-Bae Kim , Young-Hyuck Im , Seock-Ah Im , Vladimir Semiglazov , Eva Ciruelos , Andreas Schneeweiss , Estefania Monturus , Emma Clark , Adam Knott , Eleonora Restuccia , Mark Benyunes , Javier Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT00567190
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1020)
DOI
10.1200/JCO.2019.37.15_suppl.1020
Abstract #
1020
Poster Bd #
101
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.
First Author: David Miles
Poster
2023 ASCO Annual Meeting
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.
First Author: Nuhad K. Ibrahim
Poster
2017 ASCO Annual Meeting
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).
First Author: Kazutaka Narui